RT Journal Article
T1 Long-Term Outcomes of an International Cooperative Study of Intraoperative Radiotherapy Upfront Boost With Low Energy X-Rays in Breast Cancer.
A1 Sarria, Gustavo R
A1 Ramos, Maria L
A1 Palacios, Amalia
A1 Del Castillo, Ruben
A1 Castro, Felipe
A1 Calvo, Angel
A1 Cotrina, Jose M
A1 Heredia, Adela
A1 Galarreta, Jose A
A1 Fuentes-Rivera, Paola
A1 Avalos, Alicia
A1 Martinez, David A
A1 Colqui, Kevin
A1 Ziegler, Gonzalo
A1 Schmeel, Leonard Christopher
A1 Pinillos, Luis V
A1 Wenz, Frederik
A1 Giordano, Frank A
A1 Sarria, Gustavo J
A1 Sperk, Elena
K1 IORT
K1 boost
K1 breast cancer
K1 intraoperative radiotherapy
K1 whole-breast radiotherapy
AB The purpose of this study was to assess the effectivity of upfront kilovoltage intraoperative radiotherapy (IORT) as a boost in high-risk early-stage breast cancer patients from an international pooled cohort. Patients from four centers in three different countries were retrospectively screened. Those with a minimum 1-year follow-up were included. Cumulative local (LR), regional (RR), and distant metastasis rates (DM) were analyzed. Additionally, the estimated overall survival (OS) was assessed. The Cox regression analysis was performed to identify failure predicting factors. A total of 653 patients from centers in Peru, Spain, and Germany were included. The median follow-up was 55 (12-180) months, and age was 58 (27-86) years. Clinical tumor (T) staging was T1 65.85%, T2 30.17%, and T3 3.98%. Positive margins were found in 7.9% and in-situ component in 20.06%. The median IORT dose was 20 (6-20). The median time from IORT to EBRT was 74.5 (13-364) days. An overall 3.4% (n = 22) of patients developed local recurrence at some point during follow-up. The 12-, 60-, and 120-month cumulative LR were 0.3%, 2.3%, and 7.9%, respectively. After multivariate analysis, only age  Upfront boost with IORT yields similar local control outcomes to those EBRT-based reports. Results from prospective trials, regarding toxicity, cosmesis, and effectivity are awaited to confirm these findings.
SN 2234-943X
YR 2022
FD 2022-03-17
LK http://hdl.handle.net/10668/20680
UL http://hdl.handle.net/10668/20680
LA en
DS RISalud
RD Apr 11, 2025